首页> 美国卫生研究院文献>Journal of Womens Health >Comparative Effectiveness of Continuous Subcutaneous Insulin Infusion Using Insulin Analogs and Multiple Daily Injections in Pregnant Women with Diabetes Mellitus: A Systematic Review and Meta-Analysis
【2h】

Comparative Effectiveness of Continuous Subcutaneous Insulin Infusion Using Insulin Analogs and Multiple Daily Injections in Pregnant Women with Diabetes Mellitus: A Systematic Review and Meta-Analysis

机译:胰岛素类似物和每日多次注射对糖尿病孕妇连续皮下注射胰岛素的比较效果:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We systematically reviewed the effectiveness and safety of continuous subcutaneous insulin infusion (CSII) with insulin analogs compared with multiple daily injections (MDI) in pregnant women with diabetes mellitus. We searched Medline®, Embase®, and the Cochrane Central Register of Controlled Trials through May 2013. Studies comparing CSII with MDI in pregnant women with diabetes mellitus were included. Studies using regular insulin CSII were excluded. We conducted meta-analyses where there were two or more comparable studies based on the type of insulin used in the MDI arm. Seven cohort studies of pregnant women with type 1 diabetes reported improvement in hemoglobin A1c (HbA1c) in both groups. Meta-analysis showed no difference in maternal and fetal outcomes for CSII versus MDI. Results were similar when CSII was compared with MDI with insulin analogs or regular insulin. Studies had moderate to high risk bias with incomplete descriptions of study methodology, populations, treatments, follow up, and outcomes. We conclude that observational studies reported similar improvements in HbA1c with CSII and MDI during pregnancy, but evidence was insufficient to rule out possible important differences between CSII and MDI for maternal and fetal outcomes. This highlights the need for future studies to examine the effectiveness and safety of CSII with insulin analogs and MDI in pregnant women with diabetes mellitus.
机译:我们系统地回顾了连续连续皮下注射胰岛素(CSII)与胰岛素类似物与每日多次注射(MDI)相比在糖尿病孕妇中的有效性和安全性。我们搜索了截至2013年5月的Medline®,Embase®和Cochrane对照试验中央登记册。纳入了对糖尿病孕妇CSII和MDI进行比较的研究。排除使用常规胰岛素CSII的研究。我们进行了荟萃分析,根据MDI组中使用的胰岛素类型,进行了两项或更多项可比较的研究。七项1型糖尿病孕妇的队列研究报告两组均改善了血红蛋白A1c(HbA1c)。荟萃分析显示CSII与MDI的母婴结局无差异。当CSII与含胰岛素类似物或常规胰岛素的MDI进行比较时,结果相似。研究具有中度到高风险偏见,对研究方法,人群,治疗,随访和结果的描述不完整。我们得出结论,观察性研究报告了妊娠期CSII和MDI对HbA1c的改善作用相似,但证据不足以排除CSII和MDI在孕产妇和胎儿结局方面可能存在的重要差异。这突出表明有必要进行进一步的研究,以检查CSII与胰岛素类似物和MDI在糖尿病孕妇中的有效性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号